Topics:
Breast Cancer • Medical Oncology
In a patient with ER/PR positive metastatic breast cancer with CNS disease progression on tamoxifen, would you consider AI+ palbo or capecitabine?
Being that there is limited data on CNS penetration with either regimen, what would you prefer in a patient who already received whole brain RT?
Answer from: Medical Oncologist at Academic Institution
The options for treating a patient like this could depend on a number of factors. For example, the number of brain metastases, patient performance status and level of control of extracranial disease at the time of CNS progression.
In general, if a patient has good response to the systemic disease, ...
Sign in or Register to read more